309 related articles for article (PubMed ID: 19289633)
1. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.
Böger RH; Sullivan LM; Schwedhelm E; Wang TJ; Maas R; Benjamin EJ; Schulze F; Xanthakis V; Benndorf RA; Vasan RS
Circulation; 2009 Mar; 119(12):1592-600. PubMed ID: 19289633
[TBL] [Abstract][Full Text] [Related]
2. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.
Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Pinsky DJ; Marmur JD
Coron Artery Dis; 2009 Mar; 20(2):112-7. PubMed ID: 19240644
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
Siegerink B; Maas R; Vossen CY; Schwedhelm E; Koenig W; Böger R; Rothenbacher D; Brenner H; Breitling LP
Clin Res Cardiol; 2013 Mar; 102(3):193-202. PubMed ID: 23073705
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg.
Leong T; Zylberstein D; Graham I; Lissner L; Ward D; Fogarty J; Bengtsson C; Björkelund C; Thelle D;
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):961-7. PubMed ID: 18292394
[TBL] [Abstract][Full Text] [Related]
5. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
[TBL] [Abstract][Full Text] [Related]
6. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography.
Cavusoglu E; Ruwende C; Chopra V; Poludasu S; Yanamadala S; Frishman WH; Eng C; Pinsky DJ; Marmur JD
Atherosclerosis; 2010 May; 210(1):226-31. PubMed ID: 19944421
[TBL] [Abstract][Full Text] [Related]
7. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR
Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.
Surdacki A; Kruszelnicka O; Rakowski T; Jaźwińska-Kozuba A; Dubiel JS
Cardiovasc Diabetol; 2013; 12():64. PubMed ID: 23578341
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
Tarnow L; Hovind P; Teerlink T; Stehouwer CD; Parving HH
Diabetes Care; 2004 Mar; 27(3):765-9. PubMed ID: 14988299
[TBL] [Abstract][Full Text] [Related]
10. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.
Lu TM; Chung MY; Lin MW; Hsu CP; Lin SJ
Int J Cardiol; 2011 Dec; 153(2):135-40. PubMed ID: 21794936
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
[TBL] [Abstract][Full Text] [Related]
12. Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus.
Ganz T; Wainstein J; Gilad S; Limor R; Boaz M; Stern N
Diabetes Metab Res Rev; 2017 Feb; 33(2):. PubMed ID: 27393712
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
Krzyzanowska K; Mittermayer F; Krugluger W; Schnack C; Hofer M; Wolzt M; Schernthaner G
Atherosclerosis; 2006 Nov; 189(1):236-40. PubMed ID: 16414052
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.
Schnabel R; Blankenberg S; Lubos E; Lackner KJ; Rupprecht HJ; Espinola-Klein C; Jachmann N; Post F; Peetz D; Bickel C; Cambien F; Tiret L; Münzel T
Circ Res; 2005 Sep; 97(5):e53-9. PubMed ID: 16100045
[TBL] [Abstract][Full Text] [Related]
15. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.
Meinitzer A; Kielstein JT; Pilz S; Drechsler C; Ritz E; Boehm BO; Winkelmann BR; März W
Clin Chem; 2011 Jan; 57(1):112-21. PubMed ID: 21036946
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes.
Krzyzanowska K; Mittermayer F; Wolzt M; Schernthaner G
Diabetes Care; 2007 Jul; 30(7):1834-9. PubMed ID: 17456842
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine predicts survival in the elderly.
Pizzarelli F; Maas R; Dattolo P; Tripepi G; Michelassi S; D'Arrigo G; Mieth M; Bandinelli S; Ferrucci L; Zoccali C
Age (Dordr); 2013 Dec; 35(6):2465-75. PubMed ID: 23584888
[TBL] [Abstract][Full Text] [Related]
18. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study.
Gore MO; Lüneburg N; Schwedhelm E; Ayers CR; Anderssohn M; Khera A; Atzler D; de Lemos JA; Grant PJ; McGuire DK; Böger RH
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2682-8. PubMed ID: 24008162
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
[TBL] [Abstract][Full Text] [Related]
20. Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.
Maas R; Xanthakis V; Polak JF; Schwedhelm E; Sullivan LM; Benndorf R; Schulze F; Vasan RS; Wolf PA; Böger RH; Seshadri S
Stroke; 2009 Aug; 40(8):2715-9. PubMed ID: 19498184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
